LIVTENCITY (maribavir) is now listed on the Pharmaceutical Benefits Scheme (PBS) for adult patients with post-transplant cytomegalovirus (CMV) infection or disease who are resistant, refractory or intolerant to one or more prior therapies.
CMV infection or disease has a major impact on morbidity and mortality in organ or bone marrow transplant recipients, and may lead to loss of the transplanted organ and failure of the graft.
Pharmacists have an important role in patient counselling and medication management for Livtencity, including guidance on potential side effects, drug interactions, and support with adherence during the post-transplant recovery period.
The antiviral comes in a tablet form, which can be taken as whole, crushed, or dispersed through nasogastric or orogastric tube, and is the first oral CMV treatment approved for this patient group.
"CMV can pose a significant risk for patients during the post-transplant period, highlighting the need for additional treatment options for those who are resistant, refractory or intolerant to current therapies," said Dr Tania Kew, Medical Director of Takeda Australia & New Zealand, the drug's manufacturer.
"The availability of Livtencity on the PBS provides healthcare professionals with a welcomed new option to help manage this potentially serious complication in complex transplant cases."
Learn more in the product information pamphlet HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Jul 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Jul 25
